CJC-1295 / Ipamorelin tracker
for iPhone.
CJC-1295 paired with Ipamorelin is the canonical GH-axis stack — a slow GHRH plus a clean GHRP, often co-reconstituted in one vial and dosed nightly before bed. The math gets fiddly fast: two compounds, two doses, one syringe, one timing window. Peptide Protocol treats the blend as a single first-class object so you set the per-peptide dose once and the calculator does the split.
Download Peptide Protocol — FreeCJC-1295 / Ipamorelin at a glance
Verified against the current FDA prescribing information / regulatory record. For mechanism, primary-literature sourcing, and a fuller pharmacology view, follow the cross-link to our sister site.
| Class | GHRH analog (CJC-1295) + GHRP / ghrelin mimetic (Ipamorelin) |
|---|---|
| Brand names / aliases | CJC + Ipa, GHRH/GHRP blend |
| Regulatory status | Research-only — no FDA-approved human label for either component |
| Evidence level | FDA regulatory notice / literature |
| Plasma half-life | CJC-1295 with DAC: published values ~days (not a label fact). CJC-1295 without DAC (Modified GRF 1-29): minutes-range. Ipamorelin: ~2 hours. |
| Approved presentation | No FDA-approved marketed presentation for any of the three molecules. |
| Dose initiation | No verified label dosing. Self-protocols typically pair CJC-1295 100 µg + Ipamorelin 200–300 µg nightly. |
| Side-effect notes | Limited human safety data. Ipamorelin is selective for GH release without prolactin/cortisol spikes seen in older GHRPs. |
| Key caveat | CJC-1295 (with or without DAC) and Ipamorelin are research-only. No FDA-approved human dosing exists for any of them. Doses on this page are community convention. |
For full CJC-1295 / Ipamorelin background and primary-literature sourcing, see the CJC-1295 / Ipamorelin guide on peptide-calc.app.
Built around CJC / Ipa protocols
Three things blend protocols actually need.
Blend-aware math
Define your vial as a blend with two compounds and two masses. Set per-peptide dose targets. The calculator returns the single unit count that delivers both — no spreadsheet, no second draw.
Pre-bed reminder, widget-first
Nightly cadence lives or dies by timing. Pin a widget to your home screen with the next dose time and a one-tap "Done" button. The app sends a gentle reminder; the widget keeps the window visible.
GH-axis stack support
If you layer Tesamorelin, MK-677, or BPC-157 on top, the Today screen shows the full stack with rotation, cadence, and inventory all separated. No double-draws, no mixed timing.
What it looks like
CJC-1295 / Ipamorelin — common questions
Does Peptide Protocol handle the CJC / Ipa blend in one vial?
Yes — blends are first-class in the calculator. Because neither CJC-1295 nor Ipamorelin has an FDA-approved human label, the app does not ship default doses; you define a vial with both peptides and their respective masses (e.g., 2 mg CJC-1295 + 5 mg Ipamorelin in 3 mL BAC water), enter the per-compound dose your protocol calls for, and the calculator returns the single unit count that delivers both.
CJC-1295 with DAC versus without — does the app track both?
Yes. Both are calculator presets. With-DAC has a long half-life (6–8 days) and is typically dosed once or twice weekly. No-DAC has a short half-life (~30 minutes) and is typically dosed nightly, often paired with Ipamorelin in the same draw. Choose the variant in the protocol-builder and the schedule and reminder cadence follow.
When should I dose CJC-1295 / Ipamorelin?
The most cited timing is nightly, 2–3 hours after the last meal and just before sleep, to land the GH pulse in the early-night window. The app will send a gentle reminder at the time you choose, plus widget surfaces on the home screen so you don't miss the pre-bed window.
Related peptide trackers
Track your GH-axis stack on your iPhone.
Free on the App Store. Builds your first protocol in under five minutes. No account required.
Download on the App StoreData sources
- FDA — Bulk Drug Substances Compounding Risks list
- CJC-1295 / Ipamorelin reference on peptide-calc.app
This page is fact-checked against the current regulatory record. Last verified 2026-05-09.
Not medical advice. CJC-1295 and Ipamorelin are research peptides. Neither is FDA-approved for any human indication and both are restricted under WADA in competition. The information on this page is informational and does not constitute a recommendation to use the compounds. Always consult a licensed healthcare professional before starting, modifying, or stopping any compound. See the full reference for primary sources.